Exelixis, Inc. (EXEL)

NASDAQ: EXEL · Real-Time Price · USD
36.20
-0.35 (-0.96%)
At close: Jan 17, 2025, 4:00 PM
36.36
+0.16 (0.44%)
After-hours: Jan 17, 2025, 7:58 PM EST
-0.96%
Market Cap 10.34B
Revenue (ttm) 2.08B
Net Income (ttm) 466.92M
Shares Out 285.58M
EPS (ttm) 1.55
PE Ratio 23.39
Forward PE 19.34
Dividend n/a
Ex-Dividend Date n/a
Volume 2,430,473
Open 36.76
Previous Close 36.55
Day's Range 35.99 - 36.92
52-Week Range 20.02 - 37.59
Beta 0.54
Analysts Buy
Price Target 35.50 (-1.93%)
Earnings Date Feb 4, 2025

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 7, 2000
Employees 1,310
Stock Exchange NASDAQ
Ticker Symbol EXEL
Full Company Profile

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $35.5, which is a decrease of -1.93% from the latest price.

Price Target
$35.5
(-1.93% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 a...

8 days ago - Business Wire

The Best Defensive Stocks To Hedge Against Market Uncertainty

2025 has kicked off with an air of uncertainty as investors wait to see how Donald Trump's economic agenda will impact inflation. A potential bear market presents opportunities to reassess portfolios ...

Other symbols: EXCPMPPCRTX
10 days ago - Seeking Alpha

Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza

Exelixis' stock has surged over 45% since my "Sell" rating given in March last year, driven by strong performance of cabozantinib, which remains a leading TKI for various cancers. Despite concerns ove...

11 days ago - Seeking Alpha

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) fo...

11 days ago - Business Wire

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview...

14 days ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sand...

7 weeks ago - Business Wire

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sN...

7 weeks ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November: Guggenheim...

2 months ago - Business Wire

Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine

Exelixis's Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. EXEL plans to diversify its oncology portfolio by launching one new indication for Zanza...

2 months ago - Seeking Alpha

Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript

Exelixis, Inc. (NASDAQ:EXEL) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner ...

2 months ago - Seeking Alpha

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives...

2 months ago - Business Wire

3 Attractive Biotechs With Recent Positives

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu...

Other symbols: FOLDMRKTEVAXBI
3 months ago - Seeking Alpha

Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials

Exelixis' stock has surged 51% since July 2023, significantly outperforming broader markets and breaking out of a five-year stagnation. Cabometyx, EXEL's primary revenue driver, continues to excel in ...

3 months ago - Seeking Alpha

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At ...

3 months ago - Business Wire

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-002...

3 months ago - Business Wire

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

ALAMEDA, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have ente...

Other symbols: MRK
3 months ago - Business Wire

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two ...

4 months ago - Business Wire

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX...

4 months ago - Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan St...

5 months ago - Business Wire

Exelixis Earnings Drive Share Growth

Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.

5 months ago - FXEmpire

4 Best Defensive Stocks For A Potential Soft Landing (SA Quant)

Investors are seeking stability amid the global market selloff in early August, sparked by weak jobs data and fears of an emergency interest rate cut by the Fed. Recession fears were ignited after the...

Other symbols: PPCSOTSN
5 months ago - Seeking Alpha

Exelixis: sNDA Cabometyx Expansion Could Provide Revenue Boost

Exelixis, Inc. has a PDUFA date of April 3, 2025, set to decide whether Cabometyx should be approved for the treatment of patients with advanced pancreatic neuroendocrine tumors. U.S. net product reve...

5 months ago - Seeking Alpha

Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impact

LEMONT, Ill.--(BUSINESS WIRE)--The tool — free to all users — estimates energy consumption for a wide range of vehicles, both current and future.

Other symbols: ULS
5 months ago - Business Wire

Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors

MADISON, Wisc.--(BUSINESS WIRE)--Invenra's collaboration partner, Exelixis, Inc. (NASDAQ: EXEL) has announced the initiation of the dose-escalation stage of the first-in-human phase 1 clinical trial o...

5 months ago - Business Wire

Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results

In its second-quarter earnings release, Exelixis, Inc. EXEL announced that the final overall survival (OS) analysis for the phase 3 CONTACT-02 trial has been completed.

5 months ago - Benzinga